RAFAEL HLD. overview

NEWARK, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the first quarter of fiscal year 2025 ended October 31, 2024. “We anticipate proceeding to a shareholder vote on our pending merger agreement with Cyclo Therapeutics, Inc. (Nasdaq: CYTH) in the first calendar quarter of 2025 and closing promptly post shareholder approvals. Upon closing of the merger, the Company intends to focus its strategic efforts and resources on what...

NEWARK, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the fourth quarter and the full fiscal year ended July 31, 2024. “During fiscal 2024, we made significant progress on our strategy to advance our existing portfolio and to invest in, develop and commercialize clinical stage assets in areas of high unmet medical need. Specifically, we are extremely pleased to have entered into a merger agreement with Cyclo Therapeutics...

Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 NEWARK, N.J. and GAINESVILLE, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), and Cyclo Therapeutics, Inc. (Nasdaq: CYTH) today announced that they have entered into a definitive merger agreement to...

NEWARK, N.J., June 14, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the third quarter and the first nine months of fiscal 2024 ended April 30, 2024. “During fiscal 2024, we have continued to develop our existing portfolio while actively evaluating opportunities for strategic investment,” said Bill Conkling, CEO of Rafael Holdings. Bill added, “We are particularly pleased that Cyclo Therapeutics (Nasdaq:CYTH) announced the completion...

Company remains focused on generating shareholder value by advancing portfolio and identifying attractive opportunities for strategic investments Increased ownership in Day Three Labs to a majority interest of 79% NEWARK, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the second quarter of fiscal 2024 – and the six months ended January 31, 2024. “During fiscal 2024, we will continue to focus on advancing our existing...

NEWARK, N.J., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the first quarter of fiscal 2024 - the three months ended October 31, 2023. “During fiscal 2024, we will continue to focus on advancing our existing portfolio and identifying strategic investments in companies which have the potential to generate value for our stockholders. We believe our strong balance sheet affords us the opportunity to potentially capitalize on...

NEWARK, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the fourth quarter and full year of fiscal 2023 - the three and twelve months ended July 31, 2023. “During fiscal 2023, we made meaningful progress toward expanding our portfolio through strategic investments in companies which have the potential to generate value for our stockholders. We greatly curtailed our expenses with the suspension of activities at Barer Institute...

NEWARK, N.J., June 13, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the third quarter of fiscal 2023 for the three months ended April 30, 2023, as well as the nine months ended April 30, 2023. “We continue to seek to expand our portfolio through strategic investments in companies with near term value inflection points which have the potential to generate value for our stockholders. We believe that the current dislocation in the capital...